title: Identifying chemicals with potential therapy of HIV based on protein-protein and protein-chemical interaction network.
abstract: Acquired immune deficiency syndrome (AIDS) is a severe infectious disease that causes a large number of deaths every year. Traditional anti-AIDS drugs directly targeting the HIV-1 encoded enzymes including reverse transcriptase (RT), protease (PR) and integrase (IN) usually suffer from drug resistance after a period of treatment and serious side effects. In recent years, the emergence of numerous useful information of protein-protein interactions (PPI) in the HIV life cycle and related inhibitors makes PPI a new way for antiviral drug intervention. In this study, we identified 26 core human proteins involved in PPI between HIV-1 and host, that have great potential for HIV therapy. In addition, 280 chemicals that interact with three HIV drugs targeting human proteins can also interact with these 26 core proteins. All these indicate that our method as presented in this paper is quite promising. The method may become a useful tool, or at least plays a complementary role to the existing method, for identifying novel anti-HIV drugs.
authors.affiliation: Key Laboratory of Systems Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, PR China.
authors.forename: Bi-Qing
authors.initials: BQ
authors.lastname: Li
authors.forename: Bing
authors.initials: B
authors.lastname: Niu
authors.forename: Lei
authors.initials: L
authors.lastname: Chen
authors.forename: Ze-Jun
authors.initials: ZJ
authors.lastname: Wei
authors.forename: Tao
authors.initials: T
authors.lastname: Huang
authors.forename: Min
authors.initials: M
authors.lastname: Jiang
authors.forename: Jing
authors.initials: J
authors.lastname: Lu
authors.forename: Ming-Yue
authors.initials: MY
authors.lastname: Zheng
authors.forename: Xiang-Yin
authors.initials: XY
authors.lastname: Kong
authors.forename: Yu-Dong
authors.initials: YD
authors.lastname: Cai
mesh_terms: D017485:1-Deoxynojirimycin / Q000031:analogs & derivatives / Q000737:chemistry / Q000494:pharmacology; D000465:Algorithms; D019380:Anti-HIV Agents / Q000737:chemistry* / Q000494:pharmacology; D065100:CCR5 Receptor Antagonists; D003198:Computer Simulation; D003510:Cyclohexanes / Q000737:chemistry / Q000494:pharmacology; D062126:Databases, Chemical; D016049:Didanosine / Q000737:chemistry / Q000494:pharmacology; D015195:Drug Design; D055808:Drug Discovery; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism; D054884:Host-Pathogen Interactions; D006801:Humans; D000077592:Maraviroc; D008958:Models, Molecular; D025941:Protein Interaction Mapping; D060066:Protein Interaction Maps; D019713:Receptors, CCR5 / Q000737:chemistry / Q000378:metabolism; D014230:Triazoles / Q000737:chemistry / Q000494:pharmacology
chemical_list: D019380:Anti-HIV Agents; D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes; D019713:Receptors, CCR5; D014230:Triazoles; D017485:1-Deoxynojirimycin; C059896:miglustat; D016049:Didanosine; D000077592:Maraviroc